)
BioVie (BIVI) investor relations material
BioVie Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
The annual meeting will be held virtually on November 10, 2026, with voting on director elections, auditor ratification, and an amendment to the equity incentive plan.
Shareholders of record as of September 21, 2026, are eligible to vote on the proposals.
The Board recommends voting in favor of all proposals and director nominees.
Voting matters and shareholder proposals
Proposals include electing six directors, ratifying EisnerAmper LLP as auditor for FY 2027, and amending the 2019 Omnibus Equity Incentive Plan to increase available shares from 399,509 to 3,100,000.
Voting is conducted online, by phone, or by mail, with detailed instructions provided.
Shareholders may submit proposals and nominations for the 2027 annual meeting between August 12 and September 11, 2027.
Board of directors and corporate governance
The Board consists of six members, all current directors, with a mix of industry, finance, and scientific expertise.
Five directors are considered independent under Nasdaq standards.
The Board has Audit, Compensation, and Nominating and Corporate Governance Committees, each composed solely of independent directors.
The Board held eight meetings in FY 2026, with high attendance.
A Code of Conduct and Ethics is in place, accessible on the company website.
- Bezisterim shows strong efficacy in Long COVID and Parkinson's, with phase III trials planned.BIVI
Status update - Bezisterim showed significant symptom improvement in Long COVID patients with high baseline burden.BIVI
Study result - Best efforts IPO seeks $22.7M for neuro and liver drug R&D, with up to 16M shares and warrants.BIVI
Registration filing - Net loss rose to $22.1M in FY2026; ongoing clinical trials and funding needs raise going concern doubts.BIVI
Q4 2026 - Bezisterim improved motor, non-motor symptoms, and biomarkers, supporting Phase III advancement.BIVI
Study result - Biotech seeks $70M in best efforts IPO to fund R&D amid ongoing losses and litigation risks.BIVI
Registration filing - Biotech seeks up to $70M via share and warrant offering to fund R&D, facing high risk and dilution.BIVI
Registration filing - Biotech seeks capital for late-stage neuro and liver drug programs amid ongoing losses and legal risks.BIVI
Registration filing - Bezisterim targets neuroinflammation in early Parkinson's with a novel, patient-friendly trial design.BIVI
Status Update
Next BioVie earnings date
Next BioVie earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)